Can IART's SurgiMend Relaunch Help Drive a Broader 2027 Recovery?

Integra's SurgiMend relaunch could support a broader 2027 recovery, but customer recapture and FDA approval remain key to the upside.

Zacks Investment Research • Aug 20, 2026

Is IART Still Attractive as Its Low Valuation Meets Execution Risks?

Integra's steep valuation discount meets margin gains and cost savings, but modest growth, leverage and unresolved FDA risks keep execution in focus.

Zacks Investment Research • Aug 19, 2026

Here's Why Integra LifeSciences (IART) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 5, 2026

Integra LifeSciences Q2 Earnings Call Highlights

Integra LifeSciences NASDAQ: IART reported second-quarter 2026 revenue of $419 million, up 0.8% on a reported basis and 0.7% organically from a year earlier, as improving supply reliability and operational execution supported results. Adjusted earnings per share rose 24% year over year to $0.56, exceeding the company's guidance range.

MarketBeat • Jul 29, 2026

Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript

Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jul 29, 2026

Integra LifeSciences Reports Second Quarter 2026 Financial Results

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.

GlobeNewsWire • Jul 29, 2026

Integra LifeSciences (IART) Q2 Earnings Top Estimates

Integra LifeSciences (IART) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.45 per share a year ago.

Zacks Investment Research • Jul 29, 2026

Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Jul 29, 2026

3 Stocks Showing Breakout Potential Ahead of August

Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.

Zacks Investment Research • Jul 29, 2026

Here's Why Integra LifeSciences (IART) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Jul 28, 2026